{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:45:51Z","timestamp":1792676751751,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218753","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:23:00Z","timestamp":1784614980000},"page":"218753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects"],"prefix":"10.1016","volume":"658","author":[{"given":"Ryan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinguo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-2001","authenticated-orcid":false,"given":"Hongjian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunxiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"7782","key":"10.1016\/j.canlet.2026.218753_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218753_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib9","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.canlet.2026.218753_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.canlet.2026.218753_bib14","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.canlet.2026.218753_bib16","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib18","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41587-019-0073-7","article-title":"Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy","volume":"37","author":"Kang","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218753_bib23","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving strategies for target selection for antibody-drug conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.canlet.2026.218753_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"20","key":"10.1016\/j.canlet.2026.218753_bib26","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.canlet.2026.218753_bib27","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib28","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.canlet.2026.218753_bib31","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2026.218753_bib32","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.canlet.2026.218753_bib33","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.canlet.2026.218753_bib37","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/ja00245a050","article-title":"Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I","volume":"109","author":"Lee","year":"1987","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib38","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib40","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib41","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2026.218753_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10555-012-9402-8","article-title":"Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?","volume":"32","author":"Yu","year":"2013","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/ja00759a054","article-title":"Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus","volume":"94","author":"Kupchan","year":"1972","journal-title":"J. Am. Chem. Soc."},{"issue":"20","key":"10.1016\/j.canlet.2026.218753_bib44","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2026.218753_bib45","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib47","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib49","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib50","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib51","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"issue":"17_suppl","key":"10.1016\/j.canlet.2026.218753_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib54","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib55","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib57","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218753_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib61","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib62","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/bc100480a","article-title":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","volume":"22","author":"Kellogg","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"22","key":"10.1016\/j.canlet.2026.218753_bib64","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1021\/ja00256a070","article-title":"The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10","volume":"109","author":"Pettit","year":"1987","journal-title":"J. Am. Chem. Soc."},{"issue":"6330","key":"10.1016\/j.canlet.2026.218753_bib65","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib66","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib67","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"25","key":"10.1016\/j.canlet.2026.218753_bib68","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218753_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-62703-541-5_4","article-title":"Antibody-drug conjugate payloads","volume":"1045","author":"Anderl","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib70","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acs.bioconjchem.6b00291","article-title":"Natural product splicing inhibitors: a new class of antibody-drug conjugate (ADC) payloads","volume":"27","author":"Puthenveetil","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"issue":"16","key":"10.1016\/j.canlet.2026.218753_bib72","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib73","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib75","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"24","key":"10.1016\/j.canlet.2026.218753_bib76","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","article-title":"Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates","volume":"77","author":"Caculitan","year":"2017","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.canlet.2026.218753_bib77","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib78","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib79","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin\u2019s lymphoma: target and linker-drug selection","volume":"69","author":"Polson","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib80","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib82","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10928-016-9495-8","article-title":"Quantitative characterization of in vitro bystander effect of antibody-drug conjugates","volume":"43","author":"Singh","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib83","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib84","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1208\/s12248-019-0390-2","article-title":"A systems pharmacology model for drug delivery to solid tumors by antibody-drug conjugates: implications for bystander effects","volume":"22","author":"Burton","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.canlet.2026.218753_bib86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","article-title":"Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design","volume":"181","author":"Trail","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib87","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2026.218753_bib88","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2026.218753_bib89","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib91","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2007.04.010","article-title":"Cell killing by antibody-drug conjugates","volume":"255","author":"Kovtun","year":"2007","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.canlet.2026.218753_bib92","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s11095-015-1626-1","article-title":"Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development","volume":"32","author":"Singh","year":"2015","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib93","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates: a new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib94","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.canlet.2026.218753_bib95","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib96","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib97","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218753_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib99","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"issue":"17","key":"10.1016\/j.canlet.2026.218753_bib101","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218753_bib102","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/j.canlet.2026.218753_bib103","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"Rios-Luci","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib104","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib105","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO)","volume":"25","author":"Turner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"362","key":"10.1016\/j.canlet.2026.218753_bib106","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib107","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1172\/JCI120388","article-title":"The evolving landscape of predictive biomarkers of response to PARP inhibitors","volume":"128","author":"Thomas","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.canlet.2026.218753_bib108","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C7ME00093F","article-title":"Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy","volume":"3","author":"Khera","year":"2018","journal-title":"Mol Syst Des Eng"},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib111","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib112","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib113","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"Moutafi","year":"2022","journal-title":"Lab. Invest."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"issue":"31","key":"10.1016\/j.canlet.2026.218753_bib115","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"48","key":"10.1016\/j.canlet.2026.218753_bib116","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"4_suppl","key":"10.1016\/j.canlet.2026.218753_bib117","first-page":"GS1","article-title":"Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study","volume":"82","author":"Krop","year":"2022","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.canlet.2026.218753_bib118","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib119","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrc.2017.58","article-title":"Unravelling biology and shifting paradigms in cancer with single-cell sequencing","volume":"17","author":"Baslan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2026.218753_bib120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218753_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/srep40098","article-title":"Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence","volume":"7","author":"Mazor","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib122","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib123","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.canlet.2026.218753_bib124","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.canlet.2026.218753_bib125","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib127","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","article-title":"Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells","volume":"6","author":"Szakacs","year":"2004","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"5811","key":"10.1016\/j.canlet.2026.218753_bib129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \"silent\" polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib130","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib131","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.canlet.2026.218753_bib132","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-4827(03)00342-2","article-title":"The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer","volume":"290","author":"Baker","year":"2003","journal-title":"Exp. Cell Res."},{"issue":"18","key":"10.1016\/j.canlet.2026.218753_bib133","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","article-title":"Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases","volume":"278","author":"Chen","year":"2011","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib134","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-2275(20)31588-1","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"42","author":"Dean","year":"2001","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nmeth.1315","article-title":"mRNA-Seq whole-transcriptome analysis of a single cell","volume":"6","author":"Tang","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2026.218753_bib136","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15081","article-title":"Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer","volume":"8","author":"Chung","year":"2017","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2026.218753_bib137","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","article-title":"Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity","volume":"52","author":"Kinker","year":"2020","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.canlet.2026.218753_bib138","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41556-019-0346-x","article-title":"Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments","volume":"21","author":"Janiszewska","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib139","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg3899","article-title":"High-throughput functional genomics using CRISPR-Cas9","volume":"16","author":"Shalem","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.canlet.2026.218753_bib140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib141","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.canlet.2026.218753_bib142","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib143","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody-drug conjugates","volume":"78","author":"Garcia-Alonso","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218753_bib144","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2026.218753_bib145","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib146","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2026.218753_bib147","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib148","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"158","key":"10.1016\/j.canlet.2026.218753_bib149","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.canlet.2026.218753_bib150","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.canlet.2026.218753_bib151","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218753_bib152","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"issue":"7873","key":"10.1016\/j.canlet.2026.218753_bib153","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2026.218753_bib154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:43:45Z","timestamp":1788482625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":154,"alternative-id":["S0304383526005173"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218753","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218753"}}